Viatris, Ocuphire Pharma Receive FDA Approval on Ryzumvi

Image Credit: Adobe Stock Images/Katarina

Viatris Inc. and Ocuphire Pharma, Inc. revealed that the FDA has approved Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents. The companies expect the medication to be available on a commercial level in the US during the first half of next year.

"The FDA's approval of Ryzumvi marks a significant milestone for our eye care division and underscores Viatris' commitment to advancing eye care and enhancing access for both eye care professionals and patients," said Viatris Eye Care Division President Jeffrey Nau, PhD, in a company press release."Comprehensive dilated eye exams are vital for early detection of vision-compromising diseases.Our hope is that by addressing patient dilation barriers, we're empowering eye care professionals to broaden exam availability, leading to enhanced eye health outcomes.We look forward to launching Ryzumvi in the first half of next year, and to continuing to advance our robust eye care pipeline which is aimed at addressing a range of vision-related disorders."

Reference: Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents. PR Newswire. September 27, 2023. Accessed September 28, 2023. https://www.prnewswire.com/news-releases/viatris-and-ocuphire-pharma-announce-fda-approval-of-ryzumvl-phentolamine-ophthalmic-solution-0-75-eye-drops-for-the-treatment-of-pharmacologically-induced-mydriasis-produced-by-adrenergic-agonists-eg-phenylephrine-or-par-301940275.html#:~:text=(Nasdaq:%20OCUP)%2C%20a,RYZUMVI%E2%84%A2%20(phentolamine%20ophthalmic%20solution)